ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
... syndrome. At the end of 2008, we completed a Phase IIb clinical study for ecabet
sodium and believe the recently announced positive results, in addition to ...esigns and NDA filing requirements. Based upon our further analysis of the ecabet
sodium Phase II data and results from our Xibrom lower concentration study,...
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
...Bepreve in the second half of 2009.
With regard to ecabet
sodium, our candidate for the treatment of dry eye...ing the decision to
initiate Phase III trials with ecabet
"Finally, we are noticing that the FDA i...er this year or in
early 2009, the announcement of ecabet
sodium preliminary Phase II top-line
Ecabet in Medical Technology
Ecabet in Biological Technology
ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
...nounce in the second half of 2008 top-line
data results from our additional ecabet
sodium Phase II study that we
initiated earlier this year."
studies later this year or early 2009, the announcement of ecabet
Phase II top-line results, ISTA's expectation of bringing a new prod...
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
...ement in redness and initiated both the Bepreve ocular safety study and the second Phase III study
-- Announced positive results from the ecabet
sodium Phase IIb study for the treatment of dry eye syndrome
-- Successfully completed $36.7 million financing through the private placem...